Alios BioPharma
South San Francisco · Founded 2006
About Alios BioPharma
Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).
Company Facts
- Founded: 2006
- Legal name: Alios BioPharma, Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $74.4M
- Funding stage: M&A
- Last round: Series B (Apr 2014)
- Website: aliosbiopharma.com
- Phone: 650-635-5500
Social Profiles
Canonical: https://fsome.com/organization/alios-biopharma-8414693 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.